



Market Announcement

16 October 2023

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 18 October 2023 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Senior Adviser, Listings Compliance

ASX RELEASE

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne) ASX Limited

16 October 2023

Dear Melissa

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

The Company has received new MRI data relating to its phase 2 PARA_OA_008 clinical trial investigating iPPS in knee osteoarthritis. The Company is requesting a trading halt to analyse the quantitative MRI data. Accordingly pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order to finalise its review and update to the market.

The Company requests that the trading halt remains in place until the earlier of the Company making an announcement in relation to the received PARA_OA_008 quantitative MRI data or commencement of trading on Wednesday 18 October 2023.

The Company is not aware of any reason why the trading halt should not be granted.

Authorised for release on behalf of the Board of Paradigm Biopharmaceuticals Limited.

Yours faithfully,



Abby Macnish Niven

Company Secretary